Colorectal cancer (CRC) is a serious complication of inflammatory bowel disease (IBD). 5-aminosalicylic acid (5-ASA) is commonly used in the treatment of IBD and may have chemopreventative effects against CRC. The chemoprophylatic use of 5-ASA in IBD is debatable, but the theoretical basis for a protective role for 5-ASA is sound: chronic inflammation exposes patients to inflammatory mediators of tumour development. There is considerable evidence for the efficacy of 5-ASA in mild to moderate ulcerative colitis (UC). The benefits of 5-ASA in Crohn’s disease (CD) are less clear; a recent meta-analysis showed no benefit. The European Crohn’s and Colitis Organisation (ECCO) recommend its use for prevention of CRC in UC but have not addressed its use in CD. Assessment of its potentially protective effect against CRC relies on observational studies, since logistical and ethical constraints make a randomised controlled trial impossible. However, studies have had limitations and have yielded conflicting results. Further robust observational studies are required to provide a definitive answer to this question. Despite possible cost constraints, the favourable long-term safety profile of 5-ASA justifies its chemoprophylactic use in patients with risk factors for CRC.
Share this Article
Related Content In Gastrointestinal Oncology
Advanced and Metastatic Gastrointestinal Stromal Tumours: Review of Current Knowledge and Latest Advances
touchREVIEWS in Oncology & Haematology. 2021;17(1):18-22
Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumours of the gastrointestinal (GI) tract, accounting for 0.1–3.0% of all GI malignancies, and 80% of all GI sarcomas.1–5 While GISTs can occur throughout the entire GI tract, with similar male/female incidence, 60% of cases usually present in the stomach, and about 30% in the small […]
Nivolumab for the Treatment of Esophageal Squamous Cell Carcinoma
Oncology & Hematology Review. 2020;16(2):90–4 DOI: https://doi.org/10.17925/OHR.2021.16.2.90
Esophageal cancer is the seventh most common malignancy and the sixth leading cause of death from cancer worldwide.1 The main histological subtypes are esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma. ESCC is the most common subtype, and the frequency of this disease is highest in Eastern Asia and Eastern Africa.2 In Western countries, however, the incidence […]
FOREWORD – EUROPEAN ONCOLOGY & HAEMATOLOGY – VOLUME 16 ISSUE 1 – SUMMER 2020
European Oncology & Haematology. 2020;16(1):11
Welcome to the summer edition of European Oncology & Haematology. The COVID-19 pandemic has had a devastating impact on cancer and other illness care. In addition to the heightened susceptibility of patients with cancer to infections, lockdown has resulted in delayed screening and reduced treatment of early-stage disease. However, things are starting to move in the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!